文献速递骨肿瘤创伤骨科关节外科

病理性股骨转子下骨折治疗中与假体翻修相关的因素有哪些

What Factors Are Associated With Implant Revision in the Treatment of Pathologic Subtrochanteric Femur Fractures?
PubMed 文献 · Clin Orthop Relat Res · 2024-10-22

该研究纳入113例病理性股骨转子下骨折手术患者,比较髓内钉、近端股骨置换和切开复位内固定。2年再手术累积发生率髓内钉5%、近端股骨置换15%、切开复位内固定32%,翻修累积发生率分别为4%、4%、33%。放疗抵抗肿瘤组织学(HR 8.5)和切开复位内固定(HR 6.3)与翻修相关。

要点

  • 2年翻修累积发生率:髓内钉4%、近端股骨置换4%、切开复位内固定33%(p=0.01)。
  • 放疗抵抗肿瘤组织学与翻修相关(HR 8.5,95%CI 1.2-58.9;p=0.03)。
  • 切开复位内固定与翻修相关(HR 6.3,95%CI 1.5-27.0;p=0.01)。

核心结论

  • 对于放疗抵抗肿瘤类型的病理性股骨转子下骨折,作者认为初次近端股骨置换可能更可取,因其翻修累积发生率与髓内钉无差异,同时恢复功能、缓解疼痛并提供局部肿瘤控制,且假体周围感染发生率低于挽救性近端股骨置换。
  • 对于不适合髓内钉的复杂骨折,作者建议考虑行近端股骨置换而非切开复位内固定,因翻修风险更低,且能整体替换病理性骨折并提供骨水泥假体的即刻机械稳定性。

研究设计与样本

  • 回顾性分析2000年1月至2020年12月共422例因股骨近端病理性骨折手术的患者,排除非转子下骨折301例(71%)、原发性骨肿瘤所致骨折2例(<1%)和数据不足6例(1%),最终纳入113例病理性股骨转子下骨折手术患者。
  • 中位随访6个月(范围1个月至20.6年);髓内钉77例(68%),近端股骨置换22例(19%),切开复位内固定14例(12%)。
  • 采用竞争风险分析(死亡为竞争事件)估计再手术和翻修的累积发生率,采用Cox比例风险模型识别与翻修相关的因素,所有分析均校正潜在混杂因素。

主要发现

  • 2年再手术累积发生率:髓内钉5%(95%CI 4%-6%)、近端股骨置换15%(95%CI 9%-22%)、切开复位内固定32%(95%CI 15%-50%)(p=0.03)。
  • 2年翻修累积发生率:髓内钉4%(95%CI 3%-4%)、近端股骨置换4%(95%CI 2%-6%)、切开复位内固定33%(95%CI 15%-51%)(p=0.01)。
  • 与翻修相关的因素包括放疗抵抗肿瘤组织学(HR 8.5,95%CI 1.2-58.9;p=0.03)和切开复位内固定(HR 6.3,95%CI 1.5-27.0;p=0.01)。
  • 3个月、1年、2年总体生存率分别为80%(95%CI 71%-87%)、35%(95%CI 26%-45%)、28%(95%CI 19%-36%)。
  • 30天术后并发症在各固定类型间无差异,但90天再入院率切开复位内固定最高(3/14 vs 近端股骨置换4/22 vs 髓内钉4%[3/77];p=0.03);假体周围感染在挽救性近端股骨置换中更常见(2/6 vs 初次近端股骨置换1/22;p=0.04)。

关键数值与推荐

  • 2年再手术累积发生率:髓内钉5%(95%CI 4%-6%)、近端股骨置换15%(95%CI 9%-22%)、切开复位内固定32%(95%CI 15%-50%)(p=0.03)。
  • 2年翻修累积发生率:髓内钉4%(95%CI 3%-4%)、近端股骨置换4%(95%CI 2%-6%)、切开复位内固定33%(95%CI 15%-51%)(p=0.01)。
  • 放疗抵抗肿瘤组织学与翻修相关(HR 8.5,95%CI 1.2-58.9;p=0.03)。
  • 切开复位内固定与翻修相关(HR 6.3,95%CI 1.5-27.0;p=0.01)。
  • 3个月、1年、2年总体生存率分别为80%(95%CI 71%-87%)、35%(95%CI 26%-45%)、28%(95%CI 19%-36%)。

临床怎么用

  • 对于放疗抵抗肿瘤类型的病理性股骨转子下骨折,作者认为初次近端股骨置换可能更可取。
  • 对于不适合髓内钉的复杂骨折,作者建议考虑行近端股骨置换而非切开复位内固定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limiting reoperation or revision after operative stabilization or endoprosthetic reconstruction of a pathologic subtrochanteric femur fracture reduces morbidity, but how best to achieve this remains controversial. Endoprosthetic reconstruction offers durable mechanical stability but may not be most appropriate in patients who are frail or who are not expected to survive more than a few months. For that reason, cumulative incidence survival (looking at the endpoint of reoperation or revision with death as a competing risk) and factors associated with revision after surgical stabilization or reconstruction-both of which remain poorly characterized to date-would help surgeons make better decisions on behalf of these patients. QUESTIONS/PURPOSES: We analyzed patients who were operatively treated for pathologic subtrochanteric femur fracture, and we asked: (1) What is the cumulative incidence of reoperation and revision at 3 months, 1 year, and 2 years after surgery for pathologic subtrochanteric femur fracture in patients undergoing each treatment type with death as a competing risk? (2) What are the factors associated with implant revision after operative treatment of pathologic subtrochanteric femur fracture? (3) What is the overall survival of patients in this population after surgery? (4) How do clinical and surgical factors along with the frequency of complications compare in this population by operative treatment? METHODS: Between January 2000 and December 2020, 422 patients underwent surgery for completed proximal femur pathologic fractures. After excluding patients with non-subtrochanteric femur fractures (71% [301]), fractures caused by primary tumors of bone (< 1% [2]), and insufficient data (1% [6]), we included 113 patients who underwent operative treatment of completed pathologic subtrochanteric femur fractures. Our study period spanned 20 years because although implant trends may have shifted, the overall operative objective for pathologic subtrochanteric femur fractures-restoring function and alleviating pain, regardless of the extent of bony union-have remained relatively unchanged during this period. Median follow-up time was 6 months (range 1 month to 20.6 years). Intramedullary nailing (IMN) was performed in 68% (77) of patients, proximal femur replacement (PFR) was performed in 19% (22), and open reduction and internal fixation (ORIF) was performed in 12% (14) of patients. IMN was performed in patients with a poor prognosis but in whom fracture stabilization was felt to be advantageous. In instances of complex fractures in which adequate reduction could not be achieved, ORIF was generally performed. PFR was generally performed in patients with a better prognosis in which long-term implant survival and patient function were prioritized. We found a higher proportion of women in the IMN group (73% versus 32% in PFR and 50% in ORIF; p = 0.001). Rapid growth tumors (Katagiri classification) were found in 25% of patients with IMN, 27% with PFR, and 43% with ORIF. The primary outcome was the cumulative incidence of reoperation or revision surgery after initial stabilization. Competing risk analysis with death as a competing event was performed to estimate the cumulative incidence for reoperation and revision. Factors associated with revision surgery were identified using the Cox proportional hazards model, which rendered HRs. All analyses were adjusted to control for potential confounders. RESULTS: The cumulative incidence for reoperation at 2 years was 5% (95% confidence interval [CI] 4% to 6%) for IMN, 15% (95% CI 9% to 22%) for PFR, and 32% (95% CI 15% to 50%) for ORIF (p = 0.03). The cumulative incidence for revision at 2 years was 4% (95% CI 3% to 4%) for IMN, 4% (95% CI 2% to 6%) for PFR, and 33% (95% CI 15% to 51%) for ORIF (p = 0.01). Factors associated with revision surgery were radioresistant tumor histology (HR 8.5 [95% CI 1.2 to 58.9]; p = 0.03) and ORIF (HR 6.3 [95% CI 1.5 to 27.0]; p = 0.01). The 3-month, 1-year, and 2-year overall survival was 80% (95% CI 71% to 87%), 35% (95% CI 26% to 45%), and 28% (95% CI 19% to 36%), respectively. Thirty-day postoperative complications did not differ by fixation type, but 90-day readmission was highest after ORIF (3 of 14 versus 4 of 22 in PFR and 4% [3 of 77] in IMN; p = 0.03) Periprosthetic joint infection (PJI) was more common after salvage PFR (2 of 6) than primary PFR (1 of 22) (p = 0.04). CONCLUSION: Primary PFR may be preferred for pathologic subtrochanteric femur fractures arising from radioresistant tumor types, as the cumulative incidence of revision was no different than for IMN while restoring function, alleviating pain, and offering local tumor control, and it less commonly develops PJI than salvage PFR. In complex fractures not amenable to IMN, surgeons should consider performing a PFR over ORIF because of the lower risk of revision and the added benefit of replacing the pathologic fracture altogether and offering immediate mechanical stability with a cemented endoprosthesis. Future studies might evaluate the extent of bone loss from local tumor burden, and this could be quantified and analyzed in future studies as a covariate as it may clarify when PFR is advantageous in this population. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Leland CR, Gonzalez MR, Werenski JO, et al. What Factors Are Associated With Implant Revision in the Treatment of Pathologic Subtrochanteric Femur Fractures? Clin Orthop Relat Res. 2024. PMID: 39437551. doi:10.1097/CORR.0000000000003291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。